{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:06:26Z","timestamp":1789632386475,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018557","name":"Science and Technology Project of Nantong City","doi-asserted-by":"publisher","award":["JCZ20066"],"award-info":[{"award-number":["JCZ20066"]}],"id":[{"id":"10.13039\/501100018557","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic kidney disease (CKD) is a global public health burden characterized by irreversible renal function loss and progressive fibrosis. Non-invasive biomarkers reflecting intra-renal inflammation and early tubulointerstitial injury remain an unmet clinical need. We combined bioinformatics analysis with clinical validation to characterize two immune-related genes, TNFSF14 and CD40, in CKD progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Two independent CKD transcriptomic datasets (GSE66494,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200961; GSE97709,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200948) were retrieved from the GEO database. Differentially Expressed Genes (DEGs) were screened with FDR adjustment. Clinical validation was performed in 140 CKD patients (KDIGO Stages I\u2013V) and 60 healthy controls. TNFSF14 and CD40 levels were quantified in serum\/urine via ELISA, with intra-renal expression assessed via immunofluorescence in 80 biopsy specimens. Multivariable regression was used to evaluate independent predictive value.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      TNFSF14 and CD40 were identified as core hub genes enriched in the TNF signaling pathway. Both markers were significantly elevated in serum\/urine of CKD patients (Adjusted\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05), with upregulation localized to renal tubular epithelial cells. Urinary levels increased in a CKD stage-dependent manner, positively correlating with serum creatinine\/BUN and inversely with eGFR. Urinary TNFSF14 and CD40 were independent predictors of advanced CKD, with a combined diagnostic model achieving an AUC of 0.892 (95% CI: 0.851\u20130.933).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TNFSF14 and CD40 are robust molecular signatures of tubulointerstitial injury, and their urinary levels serve as non-invasive biomarkers for CKD detection and risk stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11255-026-05138-9","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T09:54:04Z","timestamp":1777110844000},"page":"4513-4523","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated bioinformatics analysis and clinical validation identifies TNFSF14 and CD40 as novel biomarkers for chronic kidney disease progression and tubulointerstitial injury"],"prefix":"10.1007","volume":"58","author":[{"given":"Xiameng","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haonan","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanlu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyue","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"issue":"10225","key":"5138_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration (2020) Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395(10225):709\u2013733","journal-title":"Lancet"},{"issue":"1","key":"5138_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP (2022) Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl 12(1):7\u201311","journal-title":"Kidney Int Suppl"},{"issue":"5","key":"5138_CR3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41581-019-0248-y","volume":"16","author":"M Ruiz-Ortega","year":"2020","unstructured":"Ruiz-Ortega M, Rayego-Mateos S, Lamas S et al (2020) Targeting the progression of chronic kidney disease. Nat Rev Nephrol 16(5):269\u2013288","journal-title":"Nat Rev Nephrol"},{"key":"5138_CR4","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.cca.2014.08.039","volume":"438","author":"ME Wasung","year":"2015","unstructured":"Wasung ME, Chawla LS, Mito R (2015) Biomarkers of renal function, which and when? Clin Chim Acta 438:350\u2013357","journal-title":"Clin Chim Acta"},{"issue":"12","key":"5138_CR5","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1681\/ASN.2020060806","volume":"31","author":"BR Conway","year":"2020","unstructured":"Conway BR, O\u2019Sullivan ED, Cairns C et al (2020) Kidney single-cell atlas reveals myeloid heterogeneity in progression and regression of kidney disease. J Am Soc Nephrol 31(12):2833\u20132844","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"5138_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41581-019-0110-2","volume":"15","author":"PM Tang","year":"2019","unstructured":"Tang PM, Nikolic-Paterson DJ, Lan HY (2019) Macrophages: versatile players in renal inflammation and fibrosis. Nat Rev Nephrol 15(3):144\u2013158","journal-title":"Nat Rev Nephrol"},{"issue":"22","key":"5138_CR7","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1056\/NEJMra2201153","volume":"386","author":"AS Levey","year":"2022","unstructured":"Levey AS, Grams ME, Inker LA (2022) Uses of GFR and albuminuria levels in acute and chronic kidney disease. N Engl J Med 386(22):2120\u20132128","journal-title":"N Engl J Med"},{"issue":"13","key":"5138_CR8","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jama.2019.14745","volume":"322","author":"TK Chen","year":"2019","unstructured":"Chen TK, Knicely DH, Grams ME (2019) Chronic kidney disease diagnosis and management: a review. JAMA 322(13):1294\u20131304","journal-title":"JAMA"},{"issue":"1","key":"5138_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.kint.2020.10.012","volume":"99","author":"MG Shlipak","year":"2021","unstructured":"Shlipak MG, Tummalapalli SL, Boulware LE et al (2021) The case for early identification and intervention of chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 99(1):34\u201347","journal-title":"Kidney Int"},{"issue":"7841","key":"5138_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41586-020-2941-1","volume":"589","author":"C Kuppe","year":"2021","unstructured":"Kuppe C, Ibrahim MM, Kranz J et al (2021) Decoding myofibroblast origins in human kidney fibrosis. Nature 589(7841):281\u2013286","journal-title":"Nature"},{"key":"5138_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2024.117798","volume":"555","author":"E Canki","year":"2024","unstructured":"Canki E, Peco-Antic A, Spasojevic-Dimitrijeva B et al (2024) Urinary biomarkers in kidney disease. Clin Chim Acta 555:117798","journal-title":"Clin Chim Acta"},{"issue":"1","key":"5138_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1152\/physrev.00045.2017","volume":"99","author":"C Dostert","year":"2019","unstructured":"Dostert C, Grusdat M, Letellier E et al (2019) The TNF family of ligands and receptors: communication modules in the immune system and beyond. Physiol Rev 99(1):115\u2013160","journal-title":"Physiol Rev"},{"issue":"5","key":"5138_CR13","first-page":"381","volume":"41","author":"JG Skeate","year":"2020","unstructured":"Skeate JG, Otsano V, Guerrero D et al (2020) TNFSF14: LIGHTing the way for effective cancer immunotherapy. Trends Immunol 41(5):381\u2013397","journal-title":"Trends Immunol"},{"key":"5138_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.995061","volume":"13","author":"L Strohm","year":"2022","unstructured":"Strohm L, Ubbens H, M\u00fcnzel T et al (2022) Role of CD40(L)\u2013TRAF signaling in inflammation and resolution\u2014a double-edged sword. Front Pharmacol 13:995061","journal-title":"Front Pharmacol"},{"issue":"11","key":"5138_CR15","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.3390\/jcm9113653","volume":"9","author":"S Zhang","year":"2020","unstructured":"Zhang S, Breidenbach JD, Russell BH et al (2020) CD40\/CD40L signaling as a promising therapeutic target for the treatment of renal disease. J Clin Med 9(11):3653","journal-title":"J Clin Med"},{"issue":"3","key":"5138_CR16","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.kint.2017.09.033","volume":"93","author":"BC Liu","year":"2018","unstructured":"Liu BC, Tang TT, Lv LL et al (2018) Renal tubule injury: a driving force toward chronic kidney disease. Kidney Int 93(3):568\u2013579","journal-title":"Kidney Int"},{"issue":"8","key":"5138_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24086997","volume":"24","author":"CY Hsu","year":"2023","unstructured":"Hsu CY, Huang CY, Shih CM et al (2023) Tumor necrosis factor superfamily 14 (LIGHT) restricts neovascularization by decreasing circulating endothelial progenitor cells and function. Int J Mol Sci 24(8):6997","journal-title":"Int J Mol Sci"},{"issue":"7","key":"5138_CR18","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/ki.2008.350","volume":"74","author":"LG Fine","year":"2008","unstructured":"Fine LG, Norman JT (2008) Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 74(7):867\u2013872","journal-title":"Kidney Int"},{"issue":"22","key":"5138_CR19","doi-asserted-by":"publisher","first-page":"10903","DOI":"10.3390\/ijms262210903","volume":"26","author":"CY Tsai","year":"2025","unstructured":"Tsai CY, Wu TH, Ou SM et al (2025) The pathogenesis, potential biomarkers and novel therapeutic strategies for tubulointerstitial nephritis in systemic lupus erythematosus-a narrative review. Int J Mol Sci 26(22):10903","journal-title":"Int J Mol Sci"},{"issue":"24","key":"5138_CR20","doi-asserted-by":"publisher","first-page":"25469","DOI":"10.18632\/aging.104151","volume":"12","author":"Y Li","year":"2020","unstructured":"Li Y, Tang M, Han B et al (2020) Tumor necrosis factor superfamily 14 is critical for the development of renal fibrosis. Aging (Albany NY) 12(24):25469\u201325486","journal-title":"Aging (Albany NY)"},{"key":"5138_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.mam.2018.06.002","volume":"65","author":"S Djudjaj","year":"2019","unstructured":"Djudjaj S, Boor P (2019) Cellular and molecular mechanisms of kidney fibrosis. Mol Aspects Med 65:16\u201336","journal-title":"Mol Aspects Med"},{"key":"5138_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00073","volume":"4","author":"CP Argyropoulos","year":"2017","unstructured":"Argyropoulos CP, Chen SS, Ng YH et al (2017) Rediscovering beta-2 microglobulin as a biomarker across the spectrum of kidney diseases. Front Med 4:73","journal-title":"Front Med"},{"issue":"1","key":"5138_CR23","doi-asserted-by":"publisher","first-page":"7942","DOI":"10.1038\/s41598-017-08426-8","volume":"7","author":"JX Xie","year":"2017","unstructured":"Xie JX, Alderson H, Ritchie J et al (2017) Circulating CD40 and sCD40L predict changes in renal function and cardiovascular outcomes in patients with chronic kidney disease. Sci Rep 7(1):7942","journal-title":"Sci Rep"},{"issue":"1","key":"5138_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-024-03819-0","volume":"25","author":"HHL Wu","year":"2024","unstructured":"Wu HHL, Possell M, Nguyen LT et al (2024) Evaluation of urinary volatile organic compounds as a novel metabolomic biomarker to assess chronic kidney disease progression. BMC Nephrol 25(1):352","journal-title":"BMC Nephrol"},{"issue":"10","key":"5138_CR25","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1093\/ndt\/gfab294","volume":"37","author":"J Nano","year":"2022","unstructured":"Nano J, Sch\u00f6ttker B, Lin JS et al (2022) Novel biomarkers of inflammation, kidney function and chronic kidney disease in the general population. Nephrol Dial Transplant 37(10):1916\u20131926","journal-title":"Nephrol Dial Transplant"},{"key":"5138_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2025.1527814","volume":"16","author":"X Yang","year":"2025","unstructured":"Yang X, Zhao L, Pang Y (2025) TNF receptor-associated factors: promising targets of natural products for the treatment of osteoporosis. Front Physiol 16:1527814","journal-title":"Front Physiol"},{"key":"5138_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.642296","volume":"8","author":"J Portol\u00e9s","year":"2021","unstructured":"Portol\u00e9s J, Mart\u00edn L, Broseta JJ et al (2021) Anemia in chronic kidney disease: from pathophysiology and current treatments to future agents. Front Med 8:642296","journal-title":"Front Med"},{"issue":"Database issue","key":"5138_CR28","first-page":"D991","volume":"41","author":"T Barrett","year":"2013","unstructured":"Barrett T, Wilhite SE, Ledoux P et al (2013) NCBI GEO: archive for functional genomics data sets\u2013update. Nucleic Acids Res 41(Database issue):D991\u2013D995","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"5138_CR29","doi-asserted-by":"publisher","first-page":"e307","DOI":"10.1016\/S2214-109X(16)00071-1","volume":"4","author":"B Ene-Iordache","year":"2016","unstructured":"Ene-Iordache B, Perico N, Bikbov B et al (2016) Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Glob Health 4(5):e307\u2013e319","journal-title":"Lancet Glob Health"},{"issue":"11","key":"5138_CR30","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1161\/CIRCRESAHA.116.308750","volume":"119","author":"J Yang","year":"2016","unstructured":"Yang J, Fang P, Yu D et al (2016) Chronic kidney disease induces inflammatory CD40+ monocyte differentiation via homocysteine elevation and DNA hypomethylation. Circ Res 119(11):1226\u20131241","journal-title":"Circ Res"},{"issue":"7","key":"5138_CR31","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1080\/14728222.2020.1762173","volume":"24","author":"S Rayego-Mateos","year":"2020","unstructured":"Rayego-Mateos S, Valdivielso JM (2020) New therapeutic targets in chronic kidney disease progression and renal fibrosis. Expert Opin Ther Targets 24(7):655\u2013670","journal-title":"Expert Opin Ther Targets"},{"issue":"8","key":"5138_CR32","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nrd.2016.67","volume":"15","author":"MD Breyer","year":"2016","unstructured":"Breyer MD, Susztak K (2016) The next generation of therapeutics for chronic kidney disease. Nat Rev Drug Discov 15(8):568\u2013588","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"5138_CR33","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.4049\/jimmunol.2000704","volume":"207","author":"V Ceglia","year":"2021","unstructured":"Ceglia V, Zurawski S, Montes M et al (2021) Anti-CD40 antibodies fused to CD40 ligand have superagonist properties. J Immunol 207(8):2060\u20132076","journal-title":"J Immunol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05138-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05138-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05138-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:52:40Z","timestamp":1789631560000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05138-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["5138"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05138-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8690385\/v1","asserted-by":"object"}]},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"25 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}